Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

President Isaac Herzog and Genesis Prize Foundation chairman Stan Polovets presented the award, praising Milei as a “moral ...

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an unspecified up-front payment, research costs ...

Pfizer Inc. (NYSE:PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug manufacturers ...

Pfizer’s CEO Albert Bourla disclosed that the company recently met with the Trump administration to discuss lowering U.S.

Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

According to the order, the administration was to set "most favored nation" price targets within 30 days. The Department of ...

As President Donald Trump vows to bridge the drug pricing gap between the U.S. and other developed countries with his “most ...

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

Pfizer Inc. plans to spend billions of dollars to join the race for a new type of cancer treatment. Similar to its competitors, Pfizer also plans to partner with a Chinese company. The company PFE ...

STORY: Pfizer CEO Albert Bourla said Monday that he and other drug companies met with the Trump administration to discuss ...

Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...